{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:19:08Z","timestamp":1793909948877,"version":"4.8.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.ygyno.2008.01.005","type":"journal-article","created":{"date-parts":[[2008,3,11]],"date-time":"2008-03-11T10:51:46Z","timestamp":1205232706000},"page":"174-181","source":"Crossref","is-referenced-by-count":115,"title":["Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin\/paclitaxel versus carboplatin\/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival"],"prefix":"10.1016","volume":"109","author":[{"given":"David S.","family":"Alberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Marth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Bidzinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Kardatzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Williamson Z.","family":"Bradford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Loutit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Kirn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary C.","family":"Clouser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurie","family":"Markman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2008.01.005_bib1","doi-asserted-by":"crossref","unstructured":"Jamal, A, et al. Cancer Statistics 2007. CA Cancer J Clin Jan-Feb 57(1):43\u201366","DOI":"10.3322\/canjclin.57.1.43"},{"key":"10.1016\/j.ygyno.2008.01.005_bib2","unstructured":"McGuire. WP. Epithelial ovarian cancer. ASCO 2000 Educational Book 2000;541\u20136."},{"key":"10.1016\/j.ygyno.2008.01.005_bib3","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.01.005_bib4","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.ygyno.2008.01.005_bib5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1200\/JCO.2003.01.517","article-title":"Biologic and immunologic therapies for ovarian cancer","volume":"21","author":"Berek","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.01.005_bib6","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.ejca.2005.03.022","article-title":"Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin","volume":"41","author":"Barton","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2008.01.005_bib7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/0959-8049(94)90430-8","article-title":"Modulation of cisplatin cytotoxicity by human recombinant interferon-\u03b3 in human ovarian cancer cell lines","volume":"30A","author":"Nehme","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2008.01.005_bib8","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/(SICI)1097-0215(19960917)67:6<826::AID-IJC12>3.0.CO;2-#","article-title":"Different effects of interferons, interleukin-1\u03b2 and tumor necrosis factor-\u03b1 in normal (OSE) and malignant human ovarian epithelial cells","volume":"67","author":"Marth","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2008.01.005_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00000421-198808000-00011","article-title":"A phase II study of the efficacy of recombinant interferon gamma in relapsing ovarian adenocarcinoma","volume":"11","author":"Welander","year":"1988","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.01.005_bib10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.1996.14.2.343","article-title":"Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second look laparotomy","volume":"14","author":"Pujade-Lauraine","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.01.005_bib11","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1054\/bjoc.1999.1053","article-title":"Interferon gamma in the first-line therapy of ovarian cancer: a randomized phase III trial","volume":"82","author":"Windbichler","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2008.01.005_bib12","first-page":"3234","article-title":"Primary peritoneal carcinoma: a review of the literature","volume":"543","author":"Chu","year":"1999","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.ygyno.2008.01.005_bib13","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/j.1525-1438.2006.00622.x","article-title":"Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I\/II study","volume":"16","author":"Marth","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2008.01.005_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"JNCI"},{"key":"10.1016\/j.ygyno.2008.01.005_bib15","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/sim.4780131308","article-title":"Interim analysis: the alpha spending function approach","volume":"13","author":"DeMets","year":"1994","journal-title":"Stat Med"},{"key":"10.1016\/j.ygyno.2008.01.005_bib16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0197-2456(84)80014-8","article-title":"Designs for group sequential tests","volume":"13","author":"Fleming","year":"1984","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ygyno.2008.01.005_bib17","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.ajog.2004.05.007","article-title":"Interferon-\u03b3 expression is an independent prognostic factor in ovarian cancer","volume":"191","author":"Marth","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2008.01.005_bib18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/1097-0142(19870201)59:3+<617::AID-CNCR2820591308>3.0.CO;2-P","article-title":"Use of interferon in the treatment of ovarian cancer as a single agent and in combination with cytotoxic drugs","volume":"59","author":"Welander","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2008.01.005_bib19","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.4049\/jimmunol.171.11.5931","article-title":"CD4+\/CD25+ regulatory cells inhibit activation of tumor primed CD4+ T cells with IFN-\u03b3-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination","volume":"171","author":"Casares","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.ygyno.2008.01.005_bib20","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2005-02-0607","article-title":"CD4+CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients","volume":"106","author":"Nishikawa","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2008.01.005_bib21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4049\/jimmunol.174.1.90","article-title":"Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells","volume":"174","author":"Prasad","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.ygyno.2008.01.005_bib22","first-page":"8643","article-title":"Depletion of CD25 (+) CD4 (+) T cells and treatment with tyrosine-related protein 2-transduced dendritic cells enhance the interferon \u03b1-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma","volume":"61","author":"Steitz","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2008.01.005_bib23","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.ygyno.2008.01.005_bib24","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/0959-8049(93)90539-R","article-title":"The prognostic value of nuclear roundness and neopterin in ovarian cancer","volume":"29A","author":"Marth","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2008.01.005_bib25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1600-0897.2005.00330.x","article-title":"Regulatory T cells in ovarian cancer: biology and therapeutic potential","volume":"54","author":"Barnett","year":"2005","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.ygyno.2008.01.005_bib26","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1158\/1078-0432.CCR-05-1244","article-title":"The expression of the regulatory T Cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer","volume":"11","author":"Wolf","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2008.01.005_bib27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.it.2006.02.008","article-title":"Interferon gamma: a crucial role in the function of induced regulatory T cells in vivo","volume":"27","author":"Wood","year":"2006","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ygyno.2008.01.005_bib28","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1200\/JCO.2005.06.150","article-title":"Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study","volume":"23","author":"Leyland-Jones","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.01.005_bib29","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.2006.07.1514","article-title":"Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia","volume":"25","author":"Wright","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825808000085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825808000085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T20:00:17Z","timestamp":1557345617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825808000085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0090825808000085"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2008.01.005","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}